Your AI-Trained Oncology Knowledge Connection!

Jeff Sharman, MD

home / authors / jeff-sharman-md

Articles

Next Steps for Acalabrutinib/Obinutuzumab in Treatment-Naive CLL

Jeff Sharman, MD

September 3rd 2024

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

Sharman Discusses ELEVATE-TN Trial Findings in CLL

Jeff Sharman, MD

August 27th 2024

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

Behind the ELEVATE-TN Trial of Acalabrutinib/Obinutuzumab in CLL

Jeff Sharman, MD

August 21st 2024

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

Understanding the Trial With Idelalisib and Rituximab

Jeff Sharman, MD

July 20th 2020

Second-Line Treatment in Chronic Lymphocytic Leukemia

Jeff Sharman, MD

July 20th 2020

Disease Testing in Chronic Lymphocytic Leukemia

Jeff Sharman, MD

July 20th 2020

First-Line Treatment in Chronic Lymphocytic Leukemia

Jeff Sharman, MD

July 20th 2020

High-Risk Chronic Lymphocytic Leukemia

Jeff Sharman, MD

July 20th 2020

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Jeff Sharman, MD

July 20th 2020

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Results for the Combination of Ublituximab and Ibrutinib in CLL

Jeff Sharman, MD

July 7th 2017

Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).